Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Graphical abstract

Saved in:
Bibliographic Details
Published inJournal of hepatology Vol. 64; no. 2; pp. 301 - 307
Main Authors Feld, Jordan J, Moreno, Christophe, Trinh, Roger, Tam, Edward, Bourgeois, Stefan, Horsmans, Yves, Elkhashab, Magdy, Bernstein, David E, Younes, Ziad, Reindollar, Robert W, Larsen, Lois, Fu, Bo, Howieson, Kevin, Polepally, Akshanth R, Pangerl, Andreas, Shulman, Nancy S, Poordad, Fred
Format Journal Article
LanguageEnglish
Published 01.02.2016
Subjects
Gastroenterology and Hepatology
LLOQ
ombitasvir
TURQUOISE-III
SVR12
pegylated interferon
INR
international normalized ratio
SVR
paritaprevir
AEs
PTV
ritonavir
hepatitis C virus
lower limit of quantification
sustained virologic response
PegIFN
dasabuvir
sustained virologic response 12 weeks post-treatment
OBV
ribavirin
DAA
DSV
CI
RBV
adverse events
GT
genotype
direct-acting antiviral
Cirrhosis
3D
r
HCV
confidence interval
Direct-acting antivirals
Online AccessGet full text
ISSN0168-8278
DOI10.1016/j.jhep.2015.10.005

Cover

More Information
Summary:Graphical abstract
ISSN:0168-8278
DOI:10.1016/j.jhep.2015.10.005